title: Assessment of Pexelizumab in Acute Myocardial Infarction (APEX AMI): a multicenter, randomized, double-blind, parallel-group, placebo-controlled study of pexelizumab in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention.
authors.affiliation: Division of Cardiology, Department of Medicine, University of Alberta, Edmonton, Alberta, Canada. paul.armstrong@ualberta.ca
authors.forename: Paul W
authors.initials: PW
authors.lastname: Armstrong
authors.forename: Peter X
authors.initials: PX
authors.lastname: Adams
authors.forename: Hussein R
authors.initials: HR
authors.lastname: Al-Khalidi
authors.forename: Christian
authors.initials: C
authors.lastname: Hamm
authors.forename: David
authors.initials: D
authors.lastname: Holmes
authors.forename: William
authors.initials: W
authors.lastname: O'Neill
authors.forename: Thomas G
authors.initials: TG
authors.lastname: Todaro
authors.forename: Alec
authors.initials: A
authors.lastname: Vahanian
authors.forename: Frans
authors.initials: F
authors.lastname: Van de Werf
authors.forename: Christopher B
authors.initials: CB
authors.lastname: Granger
mesh_terms: D015906:Angioplasty, Balloon, Coronary; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D006333:Heart Failure / Q000517:prevention & control; D006801:Humans; D007262:Infusions, Intravenous; D007275:Injections, Intravenous; D015337:Multicenter Studies as Topic / Q000379:methods; D009203:Myocardial Infarction / Q000401:mortality / Q000628:therapy*; D011292:Premedication; D016032:Randomized Controlled Trials as Topic / Q000379:methods*; D012107:Research Design; D012770:Shock, Cardiogenic / Q000517:prevention & control; D057127:Single-Chain Antibodies; D015996:Survival Rate
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D057127:Single-Chain Antibodies; C402724:pexelizumab